Gavis

Gavis Pharmaceuticals, a subsidiary of the company, has has received final approval for its Hydrocodone Bitartrate and Acetaminophen tablets from the US Food and Drug Administration (USFDA), Lupin said in a statement.

Lupin Q2 profit seen up 80%, Gavis may support revenue growth

Healthcare company Lupin is expected to show strong growth in July-September quarter due to US business. Profit is seen rising 80 percent year-on-year to Rs 736.5 crore but interest cost may limit bottomline growth, according to analysts polled by CNBC-TV18.

Lupin gets USFDA nod for generic potassium deficiency drug

Drug firm Lupin today said its subsidiary Gavis Pharmaceuticals has received final approval from the US health regulator to market potassium chloride extended release capsules, used for treating potassium deficiency in the bloodstream, in the American market.

Lupin Q1 profit seen up 48%; Goa plant, US pricing pressure key

Operating profit (EBITDA - earnings before interest, tax, depreciation and amortisation) is likely to jump 64.6 percent to Rs 1,344.2 crore and margin may expand 500 basis points to 31 percent compared with year-ago period.

Lupin off 8% on weak sales forecast; analysts fret over Goa unit

Majority of brokerages retained their ratings on the stock but half of them slashed target price, citing caution over earnings due to likely higher R&D expenses and cut in FY18 sales guidance by the company.

Lupin Q4 profit seen up 33% to Rs 726cr, US biz may drive growth

Analysts feel exclusivity on Glumetza generic & full quarter of price hikes on Fortamet generic may drive US numbers.

Lupin shares gain 1% on anti-insomnia drug launch in US

The pharma major said its US subsidiary, Lupin Pharmaceuticals Inc has launched the first product from its GAVIS pipeline, Zolpidem Sublingual tablets 1.75 mg & 3.5 mg in the US.

Lupin confident of growth in US going ahead

"I now the first half of this year has been challenging for us. Q3, you have already started seeing recovery. Q4, you will more so and into the next year, but when I think about the business from the next couple of years' perspective, we are set for growth in the US," Vinita Gupta of Lupin says.

What took mighty Lupin down!

In an interview with CNBC-TV18‘s Sonia Shenoy & Latha Venkatesh, Praful Bohra, VP- Research, Religare said that Lupin‘s numbers are weak due to decline in the US business.

Gavis arm Wintac not part of acquisition, says Lupin CFO

Ramesh said the acquisition would not be a strain on Lupin‘s balance sheet, which was virtually debt free and has a cash surplus of USD 200 million

Lupin's $880 mln Gavis buy appears expensive, say analysts

The deal will give Lupin access to specialty generic drugs and niche products in dermatology, gastro intestinal and injectables

Lupin buys US generics firm Gavis for $880 mn

The deal, which is cash-free and debt-free, widens the company's pipeline in dermatology and controlled substance products, Lupin said in a statement.

Lupin Q1 profit tanks 16%, buys US company for $ 880 mn

Another important point to note was that its Q1FY15 numbers were quite strong led by US sales and the street also had expected the company to report weak numbers.